Search
Now showing items 1-5 of 5
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
(
Elsevier
, 2018 , Article)
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new ...
Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers
(
Elsevier
, 2020 , Article)
IntroductionSpindle cell carcinoma is a rare subtype of metaplastic breast cancer (MBC), with triple-negative (TNBC: ER-/PR-/Her2-) phenotype. It is associated with a marked resistance to conventional chemotherapy and has ...
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
(
Elsevier
, 2018 , Article)
Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor cells expression (TC) of PD-L1 is an important predictor of the of response to immune check-point inhibition in NSCLC, ...
TERT gene fusions characterize a subset of metastatic Leydig cell tumors
(
Elsevier
, 2021 , Article)
Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic ...
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
(
Elsevier Ltd
, 2018 , Article)
Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ...